The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Relapsed or Refractory Multiple Myeloma
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
-
USA Mitchell Cancer Institute, Mobile, Alabama, United States, 36604
TOI Clinical Research, Cerritos, California, United States, 90703
Kaiser Permanente - Irvine, Irvine, California, United States, 92618
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States, 90017
Local Institution - 0344, Santa Rosa, California, United States, 95403
Stockton Hematology Oncology Group, Stockton, California, United States, 95204
Local Institution - 0279, Newark, Delaware, United States, 19713
Local Institution - 0341, Fort Myers, Florida, United States, 33901
Local Institution - 0342, Saint Petersburg, Florida, United States, 33705
Local Institution - 0340, West Palm Beach, Florida, United States, 33401
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2029-07-25